CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces

Berlin, Singapore, Allschwil 9-29-2023

CELLphenomics and KYAN Technologies, a vanguard combinatory drug development solutions provider, are thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patient-derived 3D (PD3D®) cell culture models provided by CELLphenomics. 

More information